Belantamab for relapsed or treatment-resistant multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 study tests belantamab mafodotin in people with multiple myeloma that has come back or is not responding to several prior treatments. It may help shrink the cancer and improve disease control when standard options have already been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed multiple myeloma (MM) and it has returned or not responded to at least four prior therapies.
- Your cancer must have stopped responding to (or progressed soon after) treatment with an anti-CD38 antibody, an immune drug (IMiD), and a proteasome inhibitor.
- You must be at least 18 years old and able to do daily activities at a level rated 0–2 (ECOG).
- Your blood counts and key organs (liver, kidneys, etc.) must be functioning well enough for treatment.
- You must be able and willing to follow strict eye care during treatment, including regular eye exams and using eye drops often.
- You cannot have certain recent treatments or procedures, other active trials, or specific serious heart/bleeding/infection conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a lower dose of belantamab mafodotin (a targeted antibody drug) with the standard dose, when combined with two other drugs (pomalidomide and dexamethasone) for multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see if a lower dose works just as well but with fewer side effects, especially on the eyes.
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
This Phase 2 trial tests whether alternating doses and schedules of belantamab mafodotin can help people with multiple myeloma that has returned or kept progressing after several prior treatments. You may be eligible if your disease has specific measurable signs and your blood counts and organs are healthy enough for study treatment.
This Phase 2 study tests whether belantamab mafodotin combined with carfilzomib, pomalidomide, and dexamethasone can better treat multiple myeloma that has come back. It may help people who have already tried other myeloma treatments but whose cancer has progressed again.
This trial tests a combination of two drugs, talquetamab and belantamab mafodotin, for people whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to see if this combination works better than using one drug alone.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.